‘Misleading’ results in colchicine COVID-19 trials meta-analysis
November 23, 2021
“While the small studies are potentially insight providing, the large studies are the only ones worth giving our attention to in the context of the meta-analysis.”
Two swings, two misses with colchicine, Vascepa in COVID-19
September 1, 2021
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.
RECOVERY trial of COVID-19 treatments stops colchicine arm
March 8, 2021
Recruitment was halted for lack of efficacy in patients hospitalized with the disease.
ColCORONA: More questions than answers for colchicine in COVID-19
February 11, 2021
Millions of dollars and thousands of patients later, the phase 3 study highlights the challenges of COVID-19–related preprint studies without peer review.
Rheumatologic disease activity an important influencer of COVID-19 death risk
February 5, 2021
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from COVID-19.
COVID-19: Another study links colchicine to better results
February 4, 2021
Brazilian trial tested gout drug against placebo in hospitalized patients.
ColCORONA: Colchicine reduces complications in outpatient COVID-19
January 25, 2021
The use of colchicine was reported to significantly reduce hospitalizations, the need for mechanical ventilation, and deaths.
The earlier the better for colchicine post-MI: COLCOT
September 14, 2020
One substudy supported in-hospital initiation of colchicine and a second offered clues as to who may respond or experience tell-tale GI events.
Advice on treating rheumatic diseases from a COVID-19 epicenter
May 13, 2020
Hospital for Special Surgery rheumatologists discuss their approach to caring for patients with rheumatic diseases within their practice during the COVID-19 pandemic.
ACR gives guidance on rheumatic disease management during pandemic
May 12, 2020
When COVID-19 is suspected, rheumatic disease patients may continue their hydroxychloroquine but other rheumatic disease treatments may need to be stopped or held.